Two UTokyo IPC Portfolio Companies Selected for AMED’s Drug Discovery Venture Ecosystem Enhancement Program
PrintUTokyo Innovation Platform Co., Ltd. (UTokyo IPC; Headquarters: Hongo, Bunkyo-ku, Tokyo; President and CEO: Kosuke Ueda) is pleased to announce that two of its portfolio companies have been selected for the 7th round of the “Strengthening Program for Pharmaceutical Startup Ecosystem for the fiscal year 2024, hosted by Japan Agency for Medical Research and Development (AMED).
Both selections were achieved with UTokyo IPC serving as the lead-certified venture capital (VC), providing hands-on support throughout the process.
Selected Research Projects:
- CORE Biomedicine Japan LLC
Research and development of a first-in-class oral small-molecule drug for the treatment of luminal cancers, including bladder cancer, pancreatic cancer, gastric cancer, and colorectal cancer.
- LiberoThera Inc.
Development of a novel cancer therapy utilizing an antibody-drug conjugate (ADC) targeting GPCR, which is highly expressed in solid tumors.
Makoto Ohori, Partner and Chief Investment Officer (CIO) of Life Sciences at UTokyo IPC, who also served as the lead-certified VC hands-on representative for this application, commented:
“We are delighted that these two companies have been selected for AMED’s ‘Drug Discovery Venture Ecosystem Enhancement Program.’ UTokyo IPC will continue to support their growth as globally competitive biotech ventures.”
For more information on AMED’s Drug Discovery Venture Ecosystem Enhancement Program, please visit:
https://www.amed.go.jp/program/list/19/02/005.html
For details on the certified VC selection results, please visit:
https://www.amed.go.jp/koubo/19/02/1902C_00061.html
For Inquiries:
Tokyo University Innovation Platform Co., Ltd.
Entrepreneur Lab 261, South Research Building, The University of Tokyo
7-3-1 Hongo, Bunkyo-ku, Tokyo
TEL: +81-3-3830-0200 / FAX: +81-3-3830-0183
Email: info2@utokyo-ipc.co.jp
Contact: Makoto (Mark) Ohori, Atsuhiro Bingo